Merck said it expects its consumer health business in Latin America to continue to grow due to the increasing demand for consumer goods in the region at a presentation at the Financial Times Latin America Healthcare and Life Sciences Summit in Miami on Sept. 29.
“Our business is well positioned to anticipating the region’s rapidly changing demographics and responding to consumers’ healthcare needs,” Merck Consumer Health President and CEO Uta Kemmerich-Keil said.
During her presentation, Kemmerich-Keil exposed consumer trends that point to the growth of digital communication and strength in the wholesale and pharmacy sector. She also said Merck’s strategic plan is to supply the demand of the emerging middle classes in the region. Kemmerich-Keil also announced the launch of a new products in Latin American region for 2016.
Latin America represented the best performance for Merck Consumer Health globally. The region was crucial to Merck for Neurobion and Floratil sales.
In Brazil, Florati registered a 34 percent net sales growth in 2014, while is expected to become the fastest growing brand in the region.
